[Home ] [Archive]    
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: year 14, Issue 56 (9-2022) ::
3 2022, 14(56): 23-26 Back to browse issues page
Evaluation of Serum Levels of Mannose Binding Lectin-2, Tenascin-C in Patients with Coronary Artery Disease (CAD)
Fariba Nabatchian 1, Maryam Rostami2 , Negin Davoudi3
1- Department of Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences
2- School of Allied Medical Sciences, Tehran University of Medical Sciences
3- Faculty of Pharmacy, Tehran University of Medical Sciences
Abstract:   (1118 Views)
Cardiovascular disease (CVD) is a leading cause of death worldwide and continues to increase in prevalence compared to previous decades, in part because of the aging of the world population. Atherosclerotic CVD starts at a very young age and progresses over time allowing sufficient time for screening and early detection of the condition. Advances in biomarker research and developments related to CVD over the past 30 years have led to more sensitive screening methods, a greater emphasis on its early detection and diagnosis, and improved treatments resulting in more favorable clinical outcomes in the community. However, the use of biomarkers for different purposes in CVD remains an important area of research that has been explored by scientists over the years and many new developments are still underway. Therefore, a detailed description of all CVD biomarkers that are currently being used or investigated for future use in the field of cardiovascular medicine is out of scope for any review article. In the present review, we do not intend to replicate the information from previous exhaustive reviews on biomarkers but highlight key statistical and clinical issues with an emphasis on methods to evaluate the incremental yield of biomarkers, including their clinical utility, a pre-requisite before any putative novel biomarker is utilized in clinical practice. In addition, we will summarize information regarding recent novel heart failure biomarkers in current practice, which are undergoing scrutiny before they can be available for clinical use, and their impact on clinical outcomes.
Article number: 3
Keywords: Cardiovascular disease (CVD) is a leading cause of death worldwide and continues to increase in prevalence compared to previous decades, in part because of the aging of the world population. Atherosclerotic CVD starts at a very young age and progresses ov
Full-Text [PDF 288 kb]   (747 Downloads)    
Type of Study: Review | Subject: بیوشیمی
Received: 2022/09/18 | Accepted: 2022/09/19 | Published: 2022/09/19
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nabatchian F, Rostami M, Davoudi N. Evaluation of Serum Levels of Mannose Binding Lectin-2, Tenascin-C in Patients with Coronary Artery Disease (CAD). 3 2022; 14 (56) : 3
URL: http://labdiagnosis.ir/article-1-508-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
year 14, Issue 56 (9-2022) Back to browse issues page
Laboratory and Diagnosis
Persian site map - English site map - Created in 0.06 seconds with 36 queries by YEKTAWEB 4645